{"id":"triamcinolone-bevacizumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Elevated intraocular pressure"},{"rate":null,"effect":"Cataract progression"},{"rate":null,"effect":"Endophthalmitis"},{"rate":null,"effect":"Retinal detachment"},{"rate":null,"effect":"Systemic hypertension"},{"rate":null,"effect":"Thromboembolic events"}]},"_chembl":{"chemblId":"CHEMBL1201583","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This combination targets both inflammatory and angiogenic pathways in ocular disease. Triamcinolone is a corticosteroid that suppresses immune-mediated inflammation, while bevacizumab is a monoclonal antibody against VEGF that reduces pathological blood vessel formation and vascular leakage. Together, they address multiple pathogenic mechanisms in retinal and choroidal diseases.","oneSentence":"Triamcinolone reduces inflammation via glucocorticoid receptor activation, while bevacizumab inhibits vascular endothelial growth factor (VEGF) to suppress neovascularization and reduce vascular permeability.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:14:29.102Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Diabetic macular edema"},{"name":"Retinal vein occlusion with macular edema"},{"name":"Age-related macular degeneration"},{"name":"Choroidal neovascularization"}]},"trialDetails":[{"nctId":"NCT07014280","phase":"PHASE4","title":"Bevacizumab Versus Triamcinolone Acetonide for the Treatment of Keloids.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kasr El Aini Hospital","startDate":"2023-09-01","conditions":"Keloids","enrollment":28},{"nctId":"NCT06882551","phase":"PHASE4","title":"Comparison of Intravitreal Bevacizumab Injection with Combination of Suprachoroidal Triamcinolone Acetonide Along with Intravitreal Bevacizumab Injection in the Treatment of Diabetic Macular Edema in Pseudophakic Patients","status":"COMPLETED","sponsor":"Khyber Teaching Hospital","startDate":"2023-04-01","conditions":"Diabetic Macular Edema (DME)","enrollment":82},{"nctId":"NCT06559488","phase":"NA","title":"IVB for Post-vitrectomy Hemorrhage in Diabetic Eyes","status":"COMPLETED","sponsor":"Universitas Padjadjaran","startDate":"2018-04-02","conditions":"Diabetic Retinopathy, Vitreous Hemorrhage","enrollment":18},{"nctId":"NCT00555594","phase":"PHASE2, PHASE3","title":"Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization","status":"COMPLETED","sponsor":"Asociación para Evitar la Ceguera en México","startDate":"2006-09","conditions":"Corneal Neovascularization","enrollment":18},{"nctId":"NCT00600301","phase":"PHASE3","title":"Vitrectomy Without Internal Limiting Membrane Removal in the Treatment of Diffuse Diabetic Macular Edema: a Comparative Kenalog Vs Bevacizumab Intravitreal Injection Vs Control Study","status":"WITHDRAWN","sponsor":"Asociación para Evitar la Ceguera en México","startDate":"2008-01","conditions":"Diffuse Diabetic Macular Edema","enrollment":""},{"nctId":"NCT00566761","phase":"PHASE4","title":"Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO","status":"TERMINATED","sponsor":"Asociación para Evitar la Ceguera en México","startDate":"2007-06","conditions":"Macular Edema, Central Retinal Vein Occlusion","enrollment":10},{"nctId":"NCT04812977","phase":"NA","title":"Comparison of Intravitreal Anti-VEGF Versus Combination Therapy in Central Retinal Vein Occlusion","status":"COMPLETED","sponsor":"Hayatabad Medical Complex","startDate":"2018-06-10","conditions":"Central Retinal Vein Occlusion With Macular Edema","enrollment":30},{"nctId":"NCT02985619","phase":"PHASE2, PHASE3","title":"Bevacizumabe or Triamcinolone for Persistent Diabetic Macular Edema","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2016-07-21","conditions":"Diabetic Macular Edema","enrollment":100},{"nctId":"NCT00887536","phase":"PHASE3","title":"A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer","status":"COMPLETED","sponsor":"NSABP Foundation Inc","startDate":"2009-05","conditions":"Breast Cancer","enrollment":1613},{"nctId":"NCT03203447","phase":"PHASE3","title":"Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO","status":"TERMINATED","sponsor":"Clearside Biomedical, Inc.","startDate":"2018-03-05","conditions":"Macular Edema, Retinal Vein Occlusion","enrollment":325},{"nctId":"NCT01572350","phase":"PHASE3","title":"Safety and Efficacy of Triamcinolone Acetonide Combined With Laser, Bevacizumab Combined With Laser Versus Laser Alone for the Treatment of Diffuse Non-tractional Diabetic Macular Edema","status":"COMPLETED","sponsor":"Hospital Universitario de Canarias","startDate":"2010-10","conditions":"Diabetic Macular Edema","enrollment":105},{"nctId":"NCT00563940","phase":"","title":"Short-term Effects of Intravitreal Bevacizumab and Triamcinolone in Patients With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2007-03","conditions":"Diabetic Macular Edema","enrollment":30},{"nctId":"NCT01774474","phase":"PHASE3","title":"PRevention of Macular EDema After Cataract Surgery","status":"COMPLETED","sponsor":"Maastricht University Medical Center","startDate":"2013-07-10","conditions":"Cystoid Macular Edema, Cataract, Diabetes Mellitus","enrollment":1127},{"nctId":"NCT00737971","phase":"PHASE4","title":"Efficacy Study of Triamcinolone and Bevacizumab Intravitreal for Treatment of Diabetic Macular Edema","status":"COMPLETED","sponsor":"Rubens Belfort Jr.","startDate":"2008-08","conditions":"Diabetic Macular Edema","enrollment":142},{"nctId":"NCT00682539","phase":"PHASE4","title":"Intraocular Anti-VEGF Compared With Intraocular Triamcinolone in Patients With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2007-10","conditions":"Diabetic Macular Edema","enrollment":71},{"nctId":"NCT00203372","phase":"PHASE2","title":"Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)","status":"COMPLETED","sponsor":"Translational Oncology Research International","startDate":"2005-05","conditions":"Breast Cancer","enrollment":6},{"nctId":"NCT02310295","phase":"NA","title":"Prospective, Randomized Clinical Trial Comparing Macular Photocoagulation With or Without Intravitreal Bevacizumab or Triamcinolone for the Treatment of Diabetic Macular Edema","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2009-01","conditions":"Diabetic Macular Edema","enrollment":45},{"nctId":"NCT00997191","phase":"PHASE3","title":"Intravitreal Bevacizumab and Triamcinolone Associated to Laser Photocoagulation for Diabetic Macular Edema(IBeTA)","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2009-10","conditions":"Diabetic Macular Edema","enrollment":12},{"nctId":"NCT01614509","phase":"NA","title":"Combined Therapy of Posterior Subtenon Triamcinolone Acetonide and Intravitreal Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion","status":"COMPLETED","sponsor":"Yeungnam University College of Medicine","startDate":"2012-01","conditions":"Branch Retinal Vein Occlusion","enrollment":45},{"nctId":"NCT00805064","phase":"PHASE3","title":"Combined Triple Procedure in Retinal Vein Occlusion (RVO)","status":"COMPLETED","sponsor":"Johann Wolfgang Goethe University Hospital","startDate":"2006-01","conditions":"Retinal Vein Occlusion","enrollment":40},{"nctId":"NCT00806169","phase":"PHASE3","title":"Combined Triple Therapy in Diabetic Retinopathy (DRP)","status":"COMPLETED","sponsor":"Johann Wolfgang Goethe University Hospital","startDate":"2006-04","conditions":"Macular Edema, Diabetic Retinopathy","enrollment":40},{"nctId":"NCT00365365","phase":"PHASE2","title":"Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-08","conditions":"Breast Cancer","enrollment":214},{"nctId":"NCT00446030","phase":"PHASE2","title":"Pilot Study of the Safety & Efficacy of Two Docetaxel-Based Regimens Plus Bevacizumab for the Adjuvant Treatment of Subjects With Node Positive or High Risk Node Negative Breast Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-03","conditions":"Breast Neoplasms","enrollment":127},{"nctId":"NCT01095809","phase":"PHASE3","title":"Efficacy, Safety and Tolerability of Repeated Dosis of Intravitreous Bevacizumab in Uveitic Macular Oedema","status":"TERMINATED","sponsor":"Hospital Clinic of Barcelona","startDate":"2010-04","conditions":"Uveitis","enrollment":5},{"nctId":"NCT00376701","phase":"PHASE2","title":"Combination Therapy for Age-Related Macular Degeneration.","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2006-09","conditions":"Age Related Macular Degeneration","enrollment":103},{"nctId":"NCT01342159","phase":"NA","title":"Intravitreal Bevacizumab and Triamcinolone in Diabetic Macular Edema","status":"COMPLETED","sponsor":"Hallym University Medical Center","startDate":"2009-03","conditions":"Diabetic Macular Edema","enrollment":80},{"nctId":"NCT01330524","phase":"PHASE1, PHASE2","title":"Comparison of Intravitreal Bevacizumab and Triamcinolone With Placebo","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2010-01","conditions":"Acute Nonarteritic Anterior Ischemic Optic Neuropathy","enrollment":16},{"nctId":"NCT00464347","phase":"PHASE2","title":"TAC-PF, Avastin® in Combination With Photodynamic Therapy to Treat Age Related Macular Degeneration","status":"TERMINATED","sponsor":"National Eye Institute (NEI)","startDate":"2007-01","conditions":"Age-Related Macular Degeneration","enrollment":100},{"nctId":"NCT00447031","phase":"NA","title":"Combination Therapy for Neovascular Age Related Macular Degeneration","status":"WITHDRAWN","sponsor":"Yonsei University","startDate":"2007-03","conditions":"Macular Degeneration","enrollment":""},{"nctId":"NCT01053858","phase":"NA","title":"Triamcinolone or Bevacizumab for Central Retinal Vein Occlusion With Poor Vision","status":"COMPLETED","sponsor":"Hallym University Medical Center","startDate":"2008-01","conditions":"Central Retinal Vein Occlusion With 20/200 or Worse Visual Acuity","enrollment":38},{"nctId":"NCT01044329","phase":"PHASE2","title":"Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Branch Retinal Vein Occlusion","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2010-01","conditions":"Branch Retinal Vein Occlusion","enrollment":90},{"nctId":"NCT00874744","phase":"PHASE2","title":"Comparison of Single Intravitreal Injection of Triamcinolone or Bevacizumab for the Treatment of Diabetic Macular Edema","status":"COMPLETED","sponsor":"Universidade Federal de Goias","startDate":"2008-03","conditions":"Diabetic Macular Edema","enrollment":13},{"nctId":"NCT00371111","phase":"PHASE1","title":"To Compare Therapeutic Effect of Intravitreal Bevacizumab and Triamcinolone in Resistant Uveitic Cystoid Macular Edema","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2006-08","conditions":"Resistant Cystoid Macular Edema","enrollment":40},{"nctId":"NCT00370370","phase":"PHASE3","title":"Intravitreal Bevacizumab vs. Bevacizumab Combined With Triamcinolone for Neovascular AMD","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2005-11","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":""},{"nctId":"NCT00468351","phase":"PHASE1","title":"Intravitreal Triamcinolone Acetonide Versus Intravitreal Bevacizumab for Refractory Diabetic Macular Edema (IBEME Study)","status":"UNKNOWN","sponsor":"University of Sao Paulo","startDate":"2006-04","conditions":"Diabetic Macular Edema","enrollment":""},{"nctId":"NCT00370422","phase":"PHASE3","title":"Bevacizumab Versus Combined Bevacizumab and Triamcinolone for Refractory Diabetic Macular Edema; a Randomized Clinical Trial","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2005-11","conditions":"Diabetic Macular Edema","enrollment":""},{"nctId":"NCT00370669","phase":"PHASE3","title":"Effect of Intravitreal Bevacizumab on Clinically Significant Macular Edema","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2005-11","conditions":"Diabetic Macular Edema","enrollment":150},{"nctId":"NCT00370630","phase":"PHASE2","title":"Intravitreal Avastin Versus Intravitreal Avastin and Triamcinolone in Central Retinal Vein Occlusion(CRVO)","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2006-08","conditions":"Retinovascular Disease","enrollment":15},{"nctId":"NCT00370539","phase":"PHASE3","title":"Combined PDT and Intravitreal Bevacizumab vs Combination of PDT, Intravitreal Bevacizumab and Triamcinolone for Neovascular AMD","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2006-09","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["triamcinolone + avastin"],"phase":"marketed","status":"active","brandName":"Triamcinolone + Bevacizumab","genericName":"Triamcinolone + Bevacizumab","companyName":"Rubens Belfort Jr.","companyId":"rubens-belfort-jr","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Triamcinolone reduces inflammation via glucocorticoid receptor activation, while bevacizumab inhibits vascular endothelial growth factor (VEGF) to suppress neovascularization and reduce vascular permeability. Used for Diabetic macular edema, Retinal vein occlusion with macular edema, Age-related macular degeneration.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}